Publication details
Kombinace obinutuzumab a venetoklax v léčbě chronické lymfocytární leukemie
| Title in English | The combination of obinutuzumab and venetoclax in the treatment of chronic lymphocytic leukemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Farmakoterapie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.farmakoterapie.cz/c7497/kombinace-obinutuzumab-a-venetoklax-v-lecbe-chronicke-lymfocytarni-leukemie |
| Keywords | chronic lymphocytic leukemia; venetoclax; obinutuzumab; first-line treatment |
| Attached files | |
| Description | Chronic lymphocytic leukemia (CLL) represents the most frequent leukemia in adults (with the incidence 6 per 100.000 in the Czech Republic). In the last years, thanks to the new targeted drugs development, we witness dramatic extension of treatment options in CLL. We can individualize the diagnostic process and treatment considering the age, comorbidities and patient’s preferences. Bcl-2 inhibitors represent one of these new targeted drugs in CLL treatment. Currently, the only one Bcl-2 inhibitor venetoclax is used in the routine clinical practice. Venetoclax treatment indications, efficacy and side effects when combined with anti-CD20 monoclonal antibody obinutuzumab will be discussed in the following text. |